Edwards Lifesciences Reports Fourth Quarter Results

Core Insights - Edwards Lifesciences reported a 13.3% increase in Q4 sales, reaching $1.57 billion, with constant currency sales growing by 11.6% [1] - The company's TAVR (Transcatheter Aortic Valve Replacement) sales grew by 12.0% to $1.16 billion, with constant currency sales increasing by 10.6% [1] - TMTT (Transcatheter Mitral and Tricuspid Therapies) sales surged over 40% to $156 million, driven by repair and replacement therapies [1] - The Q4 earnings per share (EPS) was reported at $0.11, while the adjusted EPS stood at $0.58 [1] - For the full year 2025, sales grew by 11.5%, with constant currency sales increasing by 10.7% [1]